Jean-Michel Culouscou

Title: Jean-Michel Culouscou: Innovator in Cancer Research

Introduction

Jean-Michel Culouscou is a prominent inventor based in Seattle, WA (US). He has made significant contributions to the field of cancer research, particularly through his work on receptor tyrosine kinases. His innovative approach has led to advancements in understanding and treating various cancers.

Latest Patents

Jean-Michel Culouscou holds a patent for "Antibodies to HER4," which describes the molecular cloning, expression, and biological characteristics of a novel receptor tyrosine kinase related to the epidermal growth factor receptor, termed HER4/p180.sup.erbB4. This patent discloses antibodies to HER4 and a HER4 ligand capable of inducing cellular differentiation of breast cancer cells. The patent also outlines various diagnostic and therapeutic uses of HER4-derived and HER4-related biological compositions, given the expression of HER4 in several human cancers and in certain tissues of neuronal and muscular origin. He has 1 patent to his name.

Career Highlights

Jean-Michel Culouscou is associated with Bristol-Myers Squibb Company, where he continues to contribute to groundbreaking research in oncology. His work has been instrumental in developing new therapeutic strategies for cancer treatment.

Collaborations

Throughout his career, Jean-Michel has collaborated with notable colleagues, including Gregory D Plowman and Mohammed Shoyab. These collaborations have further enhanced the impact of his research in the scientific community.

Conclusion

Jean-Michel Culouscou's innovative work in cancer research, particularly with HER4, showcases his dedication to advancing medical science. His contributions are vital in the ongoing fight against cancer, and his patents reflect his commitment to improving patient outcomes.